Clinical Pipeline

In May 2020, Arcus established a 10-year collaboration with Gilead that included a significant capital investment and equity stake by Gilead into Arcus. Under this collaboration, Gilead obtained time-limited exclusive option rights to all Arcus clinical programs arising during the collaboration term*. Arcus and Gilead are co-developing four investigational medicines, including domvanalimab (Arcus’s anti-TIGIT antibody), zimberelimab (Arcus’s anti-PD-1 molecule), quemliclustat (Arcus’s CD73 inhibitor) and etrumadenant (Arcus’s adenosine receptor antagonist). The collaboration was expanded in November 2021 and May 2023 to include research directed to two targets for oncology and two targets for inflammatory diseases.
*Arcus Biosciences retains full rights to casdatifan